Industry Newsprotein degradationclinical trialskymera therapeuticsfast track
Kymera Therapeutics Gains Analyst Attention Amid Volatility
6.1
Kymera Therapeutics shares have risen more than 28% over the past three months, with Wall Street projecting nearly 60% further upside as of January 12. Wolfe Research downgraded the stock to Peer Perform on January 6 and removed a $92 target, while BTIG and Citigroup maintained Buy ratings with $138 and $110 targets respectively. In December, the FDA granted Fast Track designation to KT-621 after positive BroADen Phase 1b results.
Key Points
- 1Stocks rose 28% in three months; Wall Street predicts ~60% upside by Jan 12.
- 2Analysts issue mixed ratings: Wolfe downgrades Jan 6, BTIG and Citi reaffirm Buy targets.
- 3FDA Fast Track for KT-621 after Phase 1b BroADen trial suggests clinical catalyst potential.
Scoring Rationale
Moderate investor-relevant update with official FDA action and analyst moves, limited by incremental novelty and promotional tone.
Sources
Public references used for this report.
Practice with real Ad Tech data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Search Campaigns by BudgetEasyHigh CPC Clicks & Poor Landing PagesMediumCampaign ROAS by Attribution ModelHard
250 free problems · No credit card
See all Ad Tech problems
